Pfizer wins approval for pneumonia vaccine
Washington, February 24, 2010
US health officials have approved Pfizer's new version of a blockbuster vaccine that fights pneumonia, meningitis and other diseases caused by pneumococcus bacteria, a company spokeswoman said.
Prevnar 13 was the most important experimental product the company acquired in last year's purchase of Wyeth. The vaccine fights 13 strains of streptococcus pneumoniae bacteria.
The original Prevnar, which targeted seven strains, was introduced in 2000 and has annual sales around $3 billion.
BMO Capital Markets analyst Robert Hazlett has estimated sales for the Prevnar franchise will hit $3.7 billion in 2012. - Reuters
More Health & Environment Stories
- Deadly new virus a 'serious risk' in hospitals
- Panasonic in top green brands ranking
- Women demand more info on advanced breast cancer
- Type 2 diabetics ‘may fast during Ramadan’
- Qatar plans $46m investment in top solar group
- Dabur launches new haircare solution
- Bahrain hospitals win Australian accreditation
- Dust haze in Bahrain ‘set to continue’
- Bahrain’s new plan to tackle power, water
- Masdar launches wind farm in Seychelles
